KBH Earnings: KB Home's Stock Falls on Weak Forward Guidance
The stock of KB Home (KBH) is down about 3% after the U.S. homebuilder lowered its full-year guidance, saying it expects further weakness in the real estate market.
Confident Investing Starts Here:
The disappointing outlook overshadowed what was otherwise a strong print from KB Home. The Los Angeles, California-based company announced Fiscal second-quarter earnings per share (EPS) of $1.50, which beat the consensus estimate of $1.47. Revenue for the quarter ended May 31 was $1.53 billion, beating the $1.51 billion expected on Wall Street.
However, both the top and bottom line numbers reported for Fiscal Q2 were lower than a year ago, when the company's EPS came in at $2.15 and its sales totaled $1.71 billion. KB Home also lowered its full-year Fiscal 2025 guidance, saying it now expects revenue of $6.30 billion to $6.50 billion, down from $6.60 billion to $7 billion previously.
Homebuilding operating income declined to $131.5 million from $188.2 million a year ago, while the company's homebuilding operating margin fell 9% from 11.1% a year earlier in the latest quarter. Also, housing gross profit fell to 19.3% from 21.1% a year ago, mainly due to price reductions and homebuyer concessions.
KB Home's net income. Source: Main Street Data
Stock Buybacks
In the company's earnings release, KB Home's CEO Jeffrey Mezger said, 'In this environment and given our strong existing land pipeline, we are scaling back our land acquisition and development investments while increasing share repurchases.'
KB Home bought back $200 million worth of common stock at an average price of $54 per share in the just completed quarter. Mezger said the company plans to continue repurchasing shares during the rest of this year.
The average selling price of a KB Home property was $488,700 during the recent quarter, down from $500,700 in the previous quarter amid ongoing softness in the real estate market. Net orders decline 13% year-over-year to 3,460, while net order value fell 21% to $1.61 billion. KBH stock has declined 18% this year.
Is KBH Stock a Buy?
The stock of KB Home has a consensus Hold rating among 14 Wall Street analysts. That rating is based on four Buy, eight Hold, and two Sell recommendations issued in the last three months. The average KBH price target of $66 implies 23.78% upside from current levels. These ratings are likely to change after the company's financial results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
21 minutes ago
- Business Insider
Why Is Impact BioMedical Stock (IBO) Up 200% Today?
Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr Ashleys Limited. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These two companies have agreed to a reverse merger that will see Dr Ashleys Limited acquire Impact BioMedical, with the combined company trading under the Dr Ashleys Limited name. The Dr Ashleys management team will lead the combined company and will also create a new Board of Directors. Dr. Kanans Visvanats, director of Dr. Ashleys Limited, said, 'By integrating Impact Biomedical's impressive IP portfolio into our R&D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health.' IBO Stock Movement Today
Business Insider
21 minutes ago
- Business Insider
Speculative Frenzy Suggests Regencell Bioscience (RGC) is a House of Cards
Regencell Bioscience Holdings (RGC), a Hong Kong-based firm claiming to treat ADHD with a proprietary blend of Chinese herbs, has surged an eye-popping 42,000% year-to-date, turning a sub-$1 penny stock into a high-flyer trading as high as $78. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Despite having no revenue and growing losses, its market capitalization now rivals that of much larger, profitable companies, raising serious questions about what is driving this extreme valuation. The most likely catalyst appears to be speculative momentum, especially after a 38-for-1 stock split triggered a massive short-term rally, which briefly quadrupled the stock before it gave back half of those gains. Given the lack of fundamentals and the sharp volatility, this setup appears driven purely by hype, not substance. With multiple red flags and no clear business case to support current prices, I'm bearish on RGC and would strongly recommend avoiding the stock. The Math Doesn't Make Sense Frequently, early-stage biotechnology firms with no revenue trade on expectations of the potential for drug candidates in the development pipeline. Those with promising clinical trial results tend to trade at higher valuations, despite operating at a loss as they burn cash to bring a treatment to market. In contrast, Regencell currently offers a treatment. Yet, according to recent SEC filings, it reported zero revenue in its latest financial statements and posted a net loss of $4.4 million in fiscal 2024. In May, for reasons that remain unclear, shares started to climb in price from under $1 to over $23 by the end of the month. In early June, the company announced a 38-for-1 stock split, which triggered a surge in buying. Companies frequently engineer a stock split when the price of their shares becomes too high to make them more affordable for retail investors, or to increase liquidity and meet investor demand. However, stock splits don't change a company's underlying value any more than cutting a pizza into smaller slices creates more food. Red Flags Abound for RGC Several factors suggest this rally lacks a sustainable foundation. First, Regencell hasn't announced substantial breakthrough clinical results, regulatory approvals, or significant partnerships. Instead, the price action appears to be driven primarily by technical factors and speculation. The company's cash flow position has flatlined since 2019. The industry that has grown around offering treatments composed of traditional Chinese medicine does offer legitimate investment opportunities, with a global market valued at approximately $250 billion and growing. Yet, in the best-case scenario, players in this space face significant regulatory hurdles in Western markets, where approval requirements present substantial challenges for herbal formulations. With little clinical data supporting its claims, Regencell would face a steep uphill climb. Second is the company's ownership structure, where insiders control over 80% of the available shares, with CEO Yat-Gai Au personally holding an 81% stake. Concentration at these levels can create artificial scarcity and extreme volatility, as very few shares trade freely in the public market. RGC has recently experienced multiple trading halts due to excessive price swings, with daily movements of 30-40%. Finally, the company is at risk as a 'going concern' as its current assets may not be sufficient to cover upcoming obligations. For a company burning through cash without generating revenue, this raises serious questions about its long-term viability. TipRanks data shows RGC to be recording multimillion-dollar annual losses since 2020. Is RGC Stock a Buy, Hold, or Sell? Wall Street analysis of the stock is limited, and there are currently no analyst recommendations. Investors conducting their due diligence on the stock will have to look elsewhere. For instance, technical analysis currently indicates a buy rating, primarily based on the stock's relative strength compared to its moving averages. However, a closer look shows some underlying divergence, with the shorter time horizon moving averages (5-day and 10-day) reflecting the pullback from last week's highs. Momentum investors will want to keep an eye on this trend, as it could continue to unwind and quickly change the technical analysis ratings. Not All That Glitters is Gold Market history is littered with episodes of speculative excess, from Dutch tulip mania to the dot-com bubble. In each case, prices eventually collapsed when reality reasserted itself and prices adjusted to reflect their actual business prospects. Given Regencell's financial position and market dynamics, this adjustment could happen quickly once momentum shifts. Those considering RGC at this point should understand they're making a highly speculative bet. While the spectacle may be fascinating to watch, participating carries risks that far outweigh potential rewards. The smart money isn't chasing this rocket ship to nowhere. Instead, it's looking for genuine opportunities in companies with real revenues from marketable products and sustainable business models.
Yahoo
an hour ago
- Yahoo
KB Home (KBH) Q2 2025 Earnings Call Highlights: Strong Financial Performance Amid Market Challenges
Total Revenue: $1.5 billion in the second quarter. Diluted Earnings Per Share (EPS): $1.50 in the second quarter. Gross Margin: 19.7%, excluding inventory-related charges. SG&A Expenses: 10.7% of housing revenues. Operating Income Margin: 9% of homebuilding revenues. Net Orders: 3,460 in the second quarter. Average Community Count: 254, a 5% increase year-over-year. Backlog: 4,776 homes valued at $2.3 billion. Average Selling Price: Approximately $489,000. Net Income: $108 million in the second quarter. Book Value Per Share: Nearly $59, a 10% year-over-year increase. Share Repurchases: $200 million in the second quarter. Land Investment: Over $513 million in land acquisition and development. Total Liquidity: $1.2 billion, including $309 million of cash. Debt to Capital Ratio: 32.2%. Release Date: June 23, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. KB Home (NYSE:KBH) delivered solid financial results in the second quarter, meeting or exceeding guidance ranges across key metrics. The company repurchased $200 million of its shares in the second quarter, demonstrating a commitment to returning cash to shareholders. Build times improved sequentially by seven days, returning to pre-pandemic levels, which contributed to exceeding delivery expectations. The company achieved a gross margin of 19.7%, excluding inventory-related charges, which was above the guidance range. KB Home (NYSE:KBH) maintained a high customer satisfaction level, receiving numerous division-level honors from Avid CX. Affordability challenges persist due to elevated mortgage interest rates and macroeconomic uncertainties, impacting consumer confidence and home purchase decisions. Net orders declined in April and May, not following the typical spring trajectory, leading to a revision of fiscal 2025 guidance. The average absorption pace per community decreased to 4.5% net orders compared to 5.5% in the previous year's second quarter. Municipal delays in utility signoffs and certificates of occupancy impacted the timing of community openings, affecting net orders. The company revised its revenue expectation for fiscal 2025 to between $6.3 billion and $6.5 billion, indicating a lower top line and contributing to lower margins. Q: What steps is KB Home taking to manage SG&A costs amid a revenue cut? A: Jeffrey Mezger, Chairman and CEO, explained that KB Home is focused on aligning overhead with revenue and scale. They are adjusting headcount based on delivery needs and exploring various cost-saving measures. The goal is to reduce the SG&A ratio back under 10% over time. Q: Can you explain the factors affecting the gross margin outlook? A: Robert Dillard, CFO, stated that the gross margin outlook is impacted by operating leverage, land costs, and regional mix. While construction cost reductions have offset some pricing pressure, the overall expectation for the full year is a margin between 19% and 19.4%. Q: How is KB Home planning to achieve its fourth-quarter closing targets? A: Rob McGibney, President and COO, highlighted improvements in build times as a key factor. The company needs to sell about 2,500 homes to meet delivery targets, which is less than last year. They are targeting high backlog turnover ratios and leveraging inventory homes for sales. Q: What is the strategy behind KB Home's pricing adjustments in response to market conditions? A: Jeffrey Mezger, CEO, emphasized that KB Home will continue to adjust pricing based on market conditions and community performance. The strategy involves offering the best value through base price adjustments rather than relying on incentives, which is already factored into their guidance. Q: How is KB Home addressing community opening delays and their impact on sales? A: Rob McGibney, COO, acknowledged that community opening delays impacted sales, resulting in missed opportunities for a couple of hundred sales. The company is enhancing coordination with municipal stakeholders to improve forecasting and responsiveness to such delays. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
